KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Revenue: 2009-2025

Historic Revenue for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $354.3 million.

  • Halozyme Therapeutics' Revenue rose 22.12% to $354.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 31.19%. This contributed to the annual value of $1.0 billion for FY2024, which is 22.44% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Revenue of $354.3 million as of Q3 2025, which was up 8.76% from $325.7 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Revenue ranged from a high of $354.3 million in Q3 2025 and a low of $89.0 million during Q1 2021.
  • Its 3-year average for Revenue is $253.6 million, with a median of $231.4 million in 2024.
  • Over the last 5 years, Halozyme Therapeutics' Revenue had its largest YoY gain of 251.12% in 2021, and its largest YoY loss of 16.19% in 2021.
  • Halozyme Therapeutics' Revenue (Quarterly) stood at $102.0 million in 2021, then spiked by 77.93% to $181.5 million in 2022, then grew by 26.75% to $230.0 million in 2023, then climbed by 29.55% to $298.0 million in 2024, then increased by 22.12% to $354.3 million in 2025.
  • Its Revenue was $354.3 million in Q3 2025, compared to $325.7 million in Q2 2025 and $264.9 million in Q1 2025.